Allergan, Inc., the makers of products like Botox and Juvederm, could end up with the first and only hyaluronic dermal filler on the market that the FDA unanimously recommends for cheek augmentation and rejuvenating age-related loss of facial volume.
Recently, the Food and Drug Administration’s General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee recently voted unanimously in favor of recommending Allergan’s facial filler Juvederm Voluma™ XC as a treatment to restore cheek volume, and that the benefits of the procedure far outweigh the potential risks.
Allergan’s new product receives support from FDA committee
This doesn’t mean the product is officially approved by the FDA…not yet, anyway. The findings of the committee aren’t binding in any way, but the FDA considers their opinion when deciding whether or not to approve a new drug or treatment. If it is approved, it will be the only treatment on the U.S. market for cheek augmentation with such a robust amount of approval from the FDA. If approved, Allergan plans to launch Juvederm Voluma™ XC in the later part of this year.
As we get older, sub-dermal tissue in the face can lose its volume, causing a sunken, tired appearance. Injectable fillers like the hyaluronic acid-based Juvederm can fill in these empty spaces, revitalizing the face and bringing back a youthful fullness. If you’re curious about dermal fillers, contact your plastic surgeon to book a consultation.